{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:26:57Z","timestamp":1761658017759,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T00:00:00Z","timestamp":1464393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jmii.2016.05.002","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T00:37:47Z","timestamp":1464914267000},"page":"260-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-4602","authenticated-orcid":false,"given":"Hirozumi","family":"Sano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazue","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2016.05.002_bib1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/jac\/dkn027","article-title":"Risk factors for breakthrough invasive fungal infection during secondary prophylaxis","volume":"61","author":"Cornely","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2016.05.002_bib2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/MPH.0b013e3181864a80","article-title":"The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan","volume":"30","author":"Kobayashi","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jmii.2016.05.002_bib3","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/cncr.24107","article-title":"Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia","volume":"115","author":"Sung","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jmii.2016.05.002_bib4","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1542\/peds.2007-2117","article-title":"Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases","volume":"121","author":"Burgos","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jmii.2016.05.002_bib5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2016.05.002_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7326\/0003-4819-118-7-199304010-00003","article-title":"Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jmii.2016.05.002_bib7","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/1097-0142(19940415)73:8<2099::AID-CNCR2820730814>3.0.CO;2-N","article-title":"Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B","volume":"73","author":"Bodey","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.jmii.2016.05.002_bib8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2016.05.002_bib9","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1056\/NEJM199110313251803","article-title":"Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole","volume":"325","author":"Wingard","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2016.05.002_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/02681219380000311","article-title":"Fluconazole in patients at risk from invasive aspergillosis","volume":"31","author":"Kappe","year":"1993","journal-title":"J Med Vet Mycol"},{"key":"10.1016\/j.jmii.2016.05.002_bib11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/424662","article-title":"Adverse reactions to voriconazole","volume":"39","author":"Boyd","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2016.05.002_bib12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/jac\/dkl108","article-title":"Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections","volume":"57","author":"den Hollander","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2016.05.002_bib13","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1086\/588844","article-title":"Hallucinations during voriconazole therapy","volume":"47","author":"Zonios","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2016.05.002_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jac\/dkh022","article-title":"Pharmacokinetic interaction between voriconazole and cyclosporin A following allogeneic bone marrow transplantation","volume":"53","author":"Groll","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2016.05.002_bib15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2005.12.032","article-title":"Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Marty","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jmii.2016.05.002_bib16","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/MPH.0b013e3182331bc7","article-title":"Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study","volume":"33","author":"Mandhaniya","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jmii.2016.05.002_bib17","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1097\/INF.0b013e3182a74233","article-title":"Voriconazole prophylaxis in children with cancer: changing outcomes and epidemiology of fungal infections","volume":"32","author":"Maron","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jmii.2016.05.002_bib18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/cncr.28524","article-title":"Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis","volume":"120","author":"Yeh","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jmii.2016.05.002_bib19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MPH.0b013e31819daf4a","article-title":"Piperacillin\/tazobactam plus ceftazidime versus sulbactam\/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients","volume":"31","author":"Kobayashi","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jmii.2016.05.002_bib20","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/pbc.21692","article-title":"A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders","volume":"51","author":"Sato","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jmii.2016.05.002_bib21","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/pbc.25148","article-title":"A randomized trial of cefozopran versus cefepime as empirical antibiotic treatment of febrile neutropenia in pediatric cancer patients","volume":"61","author":"Sarashina","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jmii.2016.05.002_bib22","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/pbc.25178","article-title":"Comparison between piperacillin\/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: a prospective, randomized study","volume":"62","author":"Sano","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jmii.2016.05.002_bib23","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2016.05.002_bib24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jmii.2016.05.002_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1179\/146532807X192516","article-title":"Invasive fungal infection in children undergoing chemotherapy for cancer","volume":"27","author":"Yeh","year":"2007","journal-title":"Ann Trop Paediatr"},{"key":"10.1016\/j.jmii.2016.05.002_bib26","first-page":"19","article-title":"Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome","volume":"19","author":"Mattiuzzi","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jmii.2016.05.002_bib27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jinf.2007.07.003","article-title":"A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML)","volume":"55","author":"Vehreschild","year":"2007","journal-title":"J Infect"},{"key":"10.1016\/j.jmii.2016.05.002_bib28","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2007-05-091942","article-title":"Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia","volume":"110","author":"Sung","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jmii.2016.05.002_bib29","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2016.05.002_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2016.05.002_bib31","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/pbc.22451","article-title":"Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age","volume":"54","author":"Shima","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jmii.2016.05.002_bib32","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2016.05.002_bib33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/bmt.2011.111","article-title":"Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT","volume":"47","author":"Molina","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jmii.2016.05.002_bib34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkp464","article-title":"Safety of triazole antifungal drugs in patients with cancer","volume":"65","author":"Cronin","year":"2010","journal-title":"Antimicrob Chemother"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118216300433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118216300433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:21:44Z","timestamp":1761657704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118216300433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1684118216300433"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2016.05.002","relation":{},"ISSN":["1684-1182"],"issn-type":[{"type":"print","value":"1684-1182"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2016.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}